GemOx±R regimen for the patients with relapsed or refractory aggressive non-Hodgkin's lymphoma

Abstract

Objective:To evaluate the efficacy and drug-related toxicity of GemOx±R (gemcitabine,oxaliplatin ± rituximab) regimen in the treatment of patients with relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL).Methods: Twenty-nine patients with histologically confirmed relapsed or refractory aggressive NHL were given GemOx±R regimen: gemcitabine 1000 mg/m~2,iv,d1 and d8;oxaliplatin 130 mg/m~2,iv,d1;with/without rituximab 375 mg/m~2,iv dO.One cycle was administrated for 21～28 days.Each patient completed at least 2 cycles.Results:Of the 29 patients,the response rate was 65.5%.Eleven patients had complete response (CR) and 8 patients had partial response (PR).The response rates of B cell and T cell lymphoma were 68.4% and 60%,respectively;the differences between the two groups were not significant (P 0.05).However inside the group of B cell lymphoma,the response rates of RGemOX and GemOx were 80% and 55.6%,respectively,with significant difference (P = 0.043).The major side effects were bone marrow depression and gastrointestinal reactions.Conclusion:GemOx+R regimen showed high efficacy with low toxicity.It is an effective salvage regimen for patients with relapsed or refractory aggressive NHL.